CHI Health Research Center is a keystone of CHI Health's vision to be a leader among America's best health systems. Through clinical research, physicians at CHI Health may offer their patients innovative, emerging treatments that are not currently available elsewhere. Participants in clinical trials play an active role in their own healthcare, gain access to new research treatments before they are widely available and help others by contributing to medical research.

What is a Clinical Trial?

A clinical trial (also clinical research) is a research study in human volunteers to answer specific health questions. Carefully conducted clinical trials are the fastest and safest way to find treatments that work in people.

Interventional trials determine whether experimental treatments or new ways of using known therapies are safe and effective under controlled environments. Observational trials address health issues in large groups of people or populations in natural settings.  More about clinical trials

Clinical trials are ongoing and some may not be listed. If you have any questions please email the CHI Health Research office or call 402-343-8511.

Condition Description Disease Site
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN) (Ref number:161) Heart
Reveal-AF (Ref number:166) Heart
An open-label, phase II, single-arm study of everolimus in combination with letrozole in the treatment of postmenopausal women with estrogen receptor positive metastatic breast cancer (Ref number:167) Breast
Boehringer Ingelheim Pharmaceuticals, Inc., “GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fibrillation” (Phase II/III)  (Ref number:162) Heart
An open-label, multicenter phase II study to examine the efficacy and safety of everolimus as second-line therapy in the treatment of patients with metastatic renal cell carcinoma (RECORD-4) (Ref number:163) Renal Cell Cancer
Cardiac SIELLO (Ref number:170)

This clinical study is a combined Pre-Market Study and Post-Approval Registry that will enroll up to 2124 subjects implanted with BIOTRONIK’s Siello pacing lead in the atrium and/or ventricle.

Cardiac REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial) (Ref number:159)

A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group STudy to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial)

Cardiac ODYSSEY (Ref number:168)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Type 2 Diabetes A Randomized, Placebo-controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus (Ref number:155)